Key result
Tirofiban-based antithrombotic therapy without stenting restores epicardial flow in young STEMI patients.
Why the study?
Young STEMI patients with high coronary thrombus burden may lack flow-limiting severe atherosclerotic stenosis, and routine stenting may increase risks such as distal embolization and stent thrombosis.
Does a no-stent management strategy using tirofiban-based antithrombotic therapy improve angiographic outcomes in young patients with STEMI and high coronary thrombus burden?
Case Report (n=4)
Does a no-stent management strategy using tirofiban-based antithrombotic therapy improve angiographic outcomes in young patients with STEMI and high coronary thrombus burden?
A no-stent management strategy using tirofiban-based antithrombotic therapy may be a feasible alternative to routine stenting in carefully selected young STEMI patients with high thrombus burden and no flow-limiting fixed lesions.
May support aspiration or deferred stenting in young STEMI with massive thrombus without stenosis; hypothesis-generating and requires prospective validation.
Atherosclerotic plaque rupture is the most common mechanism underlying ST-segment elevation myocardial infarction (STEMI); however, young patients (≤50 years old) may present with a massive coronary thrombus in the absence of clearly demonstrated flow-limiting severe atherosclerotic stenosis. Routine direct stent implantation in these highly thrombotic lesions may increase the risk of distal embolization, impaired coronary blood flow, and long-term stent thrombosis. This report describes the angiographic outcomes of a retrospective case series of four young male patients managed without permanent stent implantation using tirofiban-based antithrombotic therapy, with or without initial mechanical reperfusion, guided by clinical stabilization and Thrombolysis in Myocardial Infarction (TIMI) flow. Tirofiban-based antithrombotic therapy was followed by substantial thrombus regression, while mechanical reperfusion was used when necessary to restore epicardial flow. In carefully selected patients with preserved coronary flow, a high thrombus burden, and no clearly demonstrated flow-limiting fixed lesion, a no-stent management strategy, with or without initial mechanical reperfusion, may be considered following individualized assessment and close angiographic follow-up.
No takes yet. Share an insight, caveat, or question.
Güleşir et al. (2026) conducted a case report in ST-segment elevation myocardial infarction (STEMI) (n=4). No-stent management using tirofiban-based antithrombotic therapy was evaluated on Angiographic outcomes (thrombus regression and epicardial flow). A no-stent management strategy using tirofiban-based antithrombotic therapy resulted in substantial thrombus regression and restored epicardial flow in 4 young males with STEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: